[go: up one dir, main page]

MX2018002038A - Formulaciones clinicas. - Google Patents

Formulaciones clinicas.

Info

Publication number
MX2018002038A
MX2018002038A MX2018002038A MX2018002038A MX2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A
Authority
MX
Mexico
Prior art keywords
clinical
cells
preparations
tissue
cell
Prior art date
Application number
MX2018002038A
Other languages
English (en)
Inventor
Gay Roger
RATLIFF Judson
E Southwick Romma
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of MX2018002038A publication Critical patent/MX2018002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dentistry (AREA)

Abstract

Algunos aspectos de esta descripción proporcionan medios clí­nicos que soportan la viabilidad, eficiencia de re-distribución, y capacidad de repoblación de cólulas y tejidos durante el almacenado por hasta 48 horas o más tiempo. Los medios clí­nicos proporcionados en la presente también son útiles para irrigación clí­nica. Tambión se proporcionan en preparaciones celulares o de tejido que comprenden una población celular o tejido y un medio clí­nico como se proporciona en la presente, que son métodos para generar tales preparaciones. Tambión se describen métodos para usar los medios clí­nicos y preparaciones de cólulas y tejidos proporcionados en la presente, por ejemplo, para administrar una cantidad efectiva de cólulas o tejido a un sujeto que necesite del mismo.
MX2018002038A 2015-08-18 2016-08-18 Formulaciones clinicas. MX2018002038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Publications (1)

Publication Number Publication Date
MX2018002038A true MX2018002038A (es) 2018-07-06

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002038A MX2018002038A (es) 2015-08-18 2016-08-18 Formulaciones clinicas.
MX2022010363A MX2022010363A (es) 2015-08-18 2018-02-16 Formulaciones clinicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010363A MX2022010363A (es) 2015-08-18 2018-02-16 Formulaciones clinicas.

Country Status (16)

Country Link
US (3) US11013808B2 (es)
EP (1) EP3334415A1 (es)
JP (3) JP7043392B2 (es)
KR (3) KR102651291B1 (es)
CN (2) CN119112939A (es)
AU (2) AU2016308818B2 (es)
BR (1) BR112018003031B1 (es)
CA (1) CA2995977A1 (es)
EA (2) EA037915B1 (es)
HK (1) HK1256839A1 (es)
IL (3) IL299326A (es)
MX (2) MX2018002038A (es)
PH (1) PH12018500371B1 (es)
SG (1) SG10201913250SA (es)
TW (3) TW202417023A (es)
WO (1) WO2017031312A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN107406830A (zh) 2014-12-30 2017-11-28 细胞治疗神经科学有限公司 Rpe细胞群和制备它们的方法
CN118995872A (zh) 2015-03-23 2024-11-22 安斯泰来再生医药协会 改进的人视网膜色素（rpe）细胞和感光祖细胞的效能测定
IL299326A (en) * 2015-08-18 2023-02-01 Astellas Inst For Regenerative Medicine Clinical formulations
JP7067744B2 (ja) * 2016-06-30 2022-05-16 株式会社ヘリオス 移植用媒体
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US20210000102A1 (en) * 2017-12-29 2021-01-07 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
KR20220049618A (ko) 2019-08-28 2022-04-21 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병 치료 조성물 및 방법
TW202122577A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之方法
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CA3225810A1 (en) * 2021-07-15 2023-01-19 Joseph Piccirilli Preservative composition for nucleic acids and biological samples and methods of use
CN118871141A (zh) * 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
AU2023310144A1 (en) 2022-07-18 2025-01-02 Astellas Institute For Regenerative Medicine Methods of treating brain injury
AU2023330893A1 (en) 2022-08-23 2025-01-30 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders
WO2024172043A1 (ja) * 2023-02-14 2024-08-22 住友ファーマ株式会社 網膜色素上皮裂孔の治療薬

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
EP0562188B1 (en) * 1992-03-27 1998-09-30 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
BR9406742A (pt) 1993-06-04 1996-03-12 Biotime Inc Solução semelhante ao plasma
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
CN1152668C (zh) 1997-08-22 2004-06-09 清水制药株式会社 含有葡萄糖的制剂
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
ATE312614T1 (de) * 2000-01-11 2005-12-15 Ophtecs Corp Perfusionslösung zusammensetzungen für ophthalmische verfahren
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
SG10201912182UA (en) 2004-01-23 2020-02-27 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
KR20090043559A (ko) * 2006-08-15 2009-05-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 조절배지
CN104946591A (zh) 2007-10-12 2015-09-30 奥卡塔治疗公司 制备rpe 细胞和rpe 细胞的组合物的改良方法
BRPI0912517A2 (pt) 2008-05-06 2019-09-24 Advanced Cell Tech Inc métodos para a produção de células eritroides anucleadas dericadas de células-tronco pluripotentes
RU2010149895A (ru) 2008-05-06 2012-06-20 Эдванст Селл Текнолоджи, Инк. (Us) Колониеобразующие гемангиоклетки и неприживающиеся гемангиоклетки
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
WO2011069127A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
CA2781969A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
US11739366B2 (en) 2010-07-23 2023-08-29 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
EP3563860A1 (en) 2011-11-14 2019-11-06 Astellas Institute for Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
EP3517604A1 (en) 2011-12-06 2019-07-31 Astellas Institute for Regenerative Medicine Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
CN103783031B (zh) 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) * 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
EP3973967A1 (en) 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
AU2014233403B2 (en) 2013-03-15 2019-08-01 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
PL3189135T3 (pl) 2014-09-05 2021-12-20 Astellas Institute For Regenerative Medicine Komórki zwojowe siatkówki i ich progenitory
CN118995872A (zh) 2015-03-23 2024-11-22 安斯泰来再生医药协会 改进的人视网膜色素（rpe）细胞和感光祖细胞的效能测定
IL299326A (en) 2015-08-18 2023-02-01 Astellas Inst For Regenerative Medicine Clinical formulations
KR20220049618A (ko) 2019-08-28 2022-04-21 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병 치료 조성물 및 방법
TW202122577A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之方法
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina

Also Published As

Publication number Publication date
US11957754B2 (en) 2024-04-16
KR20180048722A (ko) 2018-05-10
US20190358330A9 (en) 2019-11-28
MX2022010363A (es) 2022-09-21
JP2018523682A (ja) 2018-08-23
SG10201913250SA (en) 2020-03-30
TW201717912A (zh) 2017-06-01
AU2022206757B2 (en) 2024-09-05
TW202245816A (zh) 2022-12-01
TW202417023A (zh) 2024-05-01
AU2016308818B2 (en) 2022-04-21
BR112018003031B1 (pt) 2023-12-26
EA202190722A1 (ru) 2021-10-29
WO2017031312A1 (en) 2017-02-23
JP2022040140A (ja) 2022-03-10
AU2022206757A1 (en) 2022-08-18
BR112018003031A2 (pt) 2018-09-18
TWI833293B (zh) 2024-02-21
JP7449915B2 (ja) 2024-03-14
EP3334415A1 (en) 2018-06-20
KR102411018B1 (ko) 2022-06-20
US11013808B2 (en) 2021-05-25
IL299326A (en) 2023-02-01
CN119112939A (zh) 2024-12-13
KR20230058544A (ko) 2023-05-03
PH12018500371B1 (en) 2023-01-20
IL257551B (en) 2022-04-01
US20210275673A1 (en) 2021-09-09
EA037915B1 (ru) 2021-06-07
CN108697641A (zh) 2018-10-23
TWI772270B (zh) 2022-08-01
JP2024074803A (ja) 2024-05-31
US20190030168A1 (en) 2019-01-31
IL291163A (en) 2022-05-01
HK1256839A1 (zh) 2019-10-04
NZ740608A (en) 2023-09-29
JP7043392B2 (ja) 2022-03-29
CA2995977A1 (en) 2017-02-23
IL257551A (en) 2018-04-30
US20240350639A1 (en) 2024-10-24
KR102651291B1 (ko) 2024-03-26
EA201890516A1 (ru) 2018-09-28
IL291163B2 (en) 2023-05-01
AU2016308818A1 (en) 2018-04-05
KR20220090583A (ko) 2022-06-29
PH12018500371A1 (en) 2018-08-29
IL291163B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2018002038A (es) Formulaciones clinicas.
CO2019011450A2 (es) Expresión transgénica selectiva de tejidos
MX2019012311A (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
MX2018005274A (es) Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
MX2017003136A (es) Implante medico/quirurgico.
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
BR112015027996A8 (pt) Organoides compreendendo células renais isoladas e suas utilizações
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
SA521421559B1 (ar) أجهزة قابلة للزرع للعلاج بالخلايا وطرق ذات الصلة
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
CO6501131A2 (es) Antagonistas de espiro-oxindol de mdm2
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
MX390753B (es) Metodos para reprogramar celulas y usos de los mismos.
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
MX2020004811A (es) Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
CR20150310A (es) Solución para preservar conductos vasculares
MX2020011406A (es) Metodos para aumentar el progreso genetico en una linea o raza de cerdo con celulas de esperma seleccionadas por sexo.
MX2018004243A (es) Regimenes de dosificacion.
UY37047A (es) Tratamiento in situ de semillas en el surco
AR099557A1 (es) Fgf-18 en trasplantes de injertos y procedimientos de ingeniería de tejido